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A B S T R A C T
In a present pilot study, performed on 11 subjects, we studied proton magnetic resonance spectroscopy (1H-MRS)
changes in early to intermediate (3-6 weeks) responders to antidepressant treatment with selective serotonin reuptake in-
hibitors (SSRIs). All subjects had diagnosis of major recurrent depression comorbid to posttraumatic stress disorder
(PTSD). Magnetic spectroscopy was done in the region of dorsolateral prefrontal cortex on a 3T MRI-unit. Participants
were selected out of the larger sample due to an early response to antidepressant treatment within 3–6 weeks, measured
with Beck Depression Inventory (BDI). We measured levels of neuronal marker N-acetyl-aspartate (NAA), choline (CHO)
and creatine (Cr). There was no difference in NAA/Cr ratios between the first and the second spectroscopic scans (p=
0.751). However, CHO/Cr ratios showed increasing trend with mean value at the first scan of 1.09 (SD=0.22) while mean
value at second scan was 1.25 (SD=0.24), displaying statically significant difference (p=0.015). In conclusion, signifi-
cant increase in choline to creatine ratio from the first to the second spectroscopic scan during the antidepressant treat-
ment, compared to almost identical values of NAA to creatine ratio, suggests increased turnover of cell membranes as a
mechanism of the early response to the antidepressant drug therapy.
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Introduction
PTSD is still an underresearched area in modern psy-
chiatry. One of the reasons behind this is a complex over-
lapping of symptoms usually seen in such patients. Both
anxiety and depression as comorbid symptoms frequen-
tly dissolve focus of clinician’s attention and mask the
underlying (and possibly leading) diagnosis of PTSD.
This is one of the reasons why in the present study we fo-
cused on a specific type of comorbidity – that of PTSD
and major depression (MDD). At first, this connection
seems plausible albeit far-fetched. However, number of
studies confirming this relation is quite significant.
For example, approximately one-third of men and
one-quarter of women who developed PTSD after being
involved in a mass-shooting also developed a major de-
pression1. In another study, similar proportion (approxi-
mately one-third of persons studied) of young urban
adults with PTSD of various origins was described as
having the same combination of symptoms2. In studies
with Vietnam veterans, proportions of subjects with
PTSD/ MDD comorbidity were even higher, ranging from
29% to 68%3. In one of the best epidemiological studies
covering the topic of PTSD in modern US society, Kessler
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et al. describe a mean »lifetime« prevalence of PTSD to be
around 8%, with mean incidence of major depression in
these individuals as high as 48%4.
Such observations, although being interesting from
both diagnostic and therapeutic standpoints, are not
without certain shortcomings. Perhaps the most inter-
esting one is described in papers by Blanchard5 and
Yehuda. Namely, according to DSM-IV, 3 (of total number
of 17) symptoms of PTSD – insomnia, impaired concen-
tration and loss of interest for things that person has
previously enjoyed, are also shared with major depres-
sion. It is therefore possible that subjects with PTSD, ex-
hibiting these symptoms (among others), are »hastily«
diagnosed with comorbid depression, providing they also
have two additional symptoms needed for MDD diagno-
sis (MDD is diagnosed in subjects having at least 5 of 9
MDD symptoms).
In the light of the above mentioned, we suspect that
PTSD/MDD comorbidity, although perhaps being over-
diagnosed to some measure, cannot be an exception. Pro-
portion of PTSD among survivors of serious trauma is re-
ported to be between 14% and 25%6, while the proportion
of individuals developing MDD after such an event is es-
timated at 26%7. The correct answer to problem of actual
PTSD/MDD prevalence in subjects with PTSD could con-
sequently be the combination of the mentioned propor-
tions, lying between 5 and 15%.
While the proportion of individuals with PTSD as a
result of various traumatic events was already men-
tioned to be in the vicinity of 8% in American population,
Croatian population, due to its recent exposure to war
trauma is significantly more affected by this problem. In
the most recent paper dealing with this issue, Priebe et
al.8 describe prevalence rates of different mental disor-
ders in 5 countries affected by recent wars in ex-Yugosla-
via. The prevalence rates in war-affected communities,
although varying, are generally very high, especially
compared to populations in Western countries9,10. Preva-
lence of MDD in war-affected communities in Croatia
was 21.1%, while the prevalence of PTSD in the same
population was 18%.
However, neither antidepressant nor psychotherapeu-
tic solution to PTSD/MDD comorbidity is as straightfor-
ward as in cases where subjects suffer from either of
these conditions11. Seeing this as a therapeutic challenge,
our goal was to objectivize positive therapeutic outcome
in such patients by using magnetic spectroscopy.
Subjects and Methods
Following the methodology described by Dow et al.12
subjects included in the outpatient PTSD program were
screened for PTSD by means of taking their clinical his-
tory and doing a mental status exam. With clinical his-
tory and status exam done, several diagnostic instru-
ments, including the Clinician-Administered PTSD Scale
(CAPS), 17-itemHamilton depression rating scale (HAM-D)
and Beck Depression Inventory were used to confirm
subjects’ diagnosis. After all procedures were done, each
case was presented at a staff meeting to discuss treat-
ment options available.
All subjects included in the study received a standard
SSRI therapy routinely used in treatment of PTSD. Dur-
ing the study period, some of the subjects attended either
individual or group psychotherapy, while some chose to
attend both. Since the scope of the interest in the present
study was comorbidity of PTSD andMDD, a clinical diag-
nosis of major depression was further prerequisite for in-
clusion. Exclusion criteria were12: (a) current drug or al-
cohol abuse/dependence, (b) primary psychotic illness
such as schizophrenia or bipolar disorder, and (c) poor
compliance or frequent missed appointments. All 28 pa-
tients meeting all inclusion and exclusion criteria were
male. Mean age of the participants was 41 years.
Over the study period, responders to antidepressant
treatment were defined as individuals whose CAPS, HAM-
-D and BDI scores decrease confirmed subjective symp-
tom improvement seen by the psychiatrist. Symptom im-
provement described in the present study was observed
over the initial treatment period of 3 to 6 weeks.
1-HMR spectroscopy was performed on a Siemens 3 T
machine, using a radiofrequency transmit/receive head
coil suited for cerebral MRI and magnetic resonance
spectroscopy. The spectroscopic volume of interest (VOI)
of 25 x 25 x 25 mm was positioned in the right dorso-
lateral prefrontal cortical region (Figure 1). The angu-
lation of the VOI was achieved either directly by appro-
priate switching of the magnetic field gradients or by
reclining the subject’s head in an adequate position. Me-
tabolite signal ratios of NAA and Cr were determined
from the spectra with TE=272 msec. Appropriate filter-
ing was applied to improve the signal to-noise ratio and
to convert the lines into a Gaussian shape.
Statistical analysis was done in Statistica software
package (Statsoft, Tulsa, OK, USA), version 8. Due to
small sample size, nonparametric methods had to be
used to compare NAA/Cr ratios before and after the
treatment. To test the null hypothesis that there is no
difference between the distributions of NAA/Cr ratios be-
fore and after antidepressant treatment was adminis-
tered, i.e. to compare paired samples of ratios, Sign test
was used.
Results
From a total number of 28 subjects discussed here, 11
could be considered as early to intermediate responders
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Fig. 1. Spectroscopic Volume of Interest (VOI) in the dorsolateral
prefrontal cortex.
to antidepressant therapy according to previously men-
tioned criteria. In all 11 subjects NAA, Cr and CHO lev-
els were measured in the DLPFC area using the above
mentioned technique before and after the 3–6 weeks
(mean value of 34,7 days; standard deviation of 6,62
days) of antidepressant treatment. Measurement results
were combined to calculate a NAA/Cr ratio and are dis-
played in Figure 2.
We found NAA/Cr ratios to be almost the same at the
baseline visit compared to the visit after the treatment.
In subjects Nos. 1, 5, 6, 9 and 10 first visit values were
higher than the second visit values, while subjects 2, 3, 7,
8 and 11 showed the opposite tendency. Subject No. 4 had
exactly the same NAA/Cr rate values at both visits. Mean
values between two visits did not differ significantly ei-
ther, with mean value at the first visit of 1.36 (SD=0.21;
–/+95% CIs of 1.22 and 1.51, respectively) and at the sec-
ond visit of 1.41 (SD=0.32; –/+ 95% CIs of 1.19 and 1.62,
respectively). Differences between measurements were
compared by the appropriate non-parametric test, as de-
scribed before and were found to be statistically not sig-
nificant (p=0.751, Z=–0.316).
On the other hand, the CHO/Cr ratios showed a dif-
ferent trend with mean values significantly higher at the
second visit, compared to the first one. Only one out of 11
subjects studied (subject No. 1) had higher CHO/Cr ratio
at the first visit, while the remaining 10 subjects all
showed higher ratios after the treatment (Figure 3).
Mean value of CHO/Cr ratio at the first visit was 1.09
(SD=0.22; –/+ 95% CIs were 0.95 and 1.24, respectively),
while at the second visit it was 1.25 (SD=0.24; –/+95%
CIs of 1.09 and 1.41, respectively). Unlike the NAA/Cr
ratios discussed before, CHO/Cr ratios differed signifi-
cantly before and after 3–6 weeks of treatment with
p-value of 0.015 (Z=2.41).
The conclusion can be made that there was no statis-
tically significant increase in NAA/Cr ratios after 3–6
weeks of antidepressant treatment in subjects with PTSD/
MDD comorbidity, while the CHO/Cr ratios increased
significantly over the same period.
Discussion
In the present study, we demonstrated that CHO/Cr
ratios increase in early (after the initial treatment period
of 3–6 weeks) responders to antidepressant treatment
among patients suffering from MDD comorbid to PTSD,
while the NAA/Cr ratios showed no statistically signifi-
cant differences between the initial and the post-treat-
ment visit. The latter finding supports the opinion that
NAA/Cr ratios have inverse relation to illness duration13,
so in our sample with short inter-observation interval,
these ratios could not change significantly. On the other
hand, CHO/Cr relation to MDD is described before as be-
ing both higher19 and lower14 in MDD patients, while it is
known to be a predictor of Alzheimer’s disease (AD) in
elderly15. However, in perhaps the most ambitious review
article about this issue, authors found CHO/Cr ratios
over the study period to increase in some studies, de-
crease in others, while in most cases the changes re-
mained non significant16.
Of the more recent studies, only a few were performed
to evaluate pre- and post-treatment NAA/Cr and CHO/Cr
changes in DLPFC brain metabolites measurable by 1H-
-MRS in depression. Kaymak et al., analyzing change in
DLPFC metabolite ratios in female MDD patients did
not find any post-treatment changes in CHO/Cr ratios,
compared to healthy controls. However, authors do de-
scribe changes in inositol (Ino) to Cr ratios after the
treatment17. Being primarily a glial-cell marker, Ino lev-
els are associated with various aspects of depressive
disorder18, from lower post-mortem values19, to decrea-
sed levels in suicide victims20. Any future study should
clearly consider this marker as well as the ones described
before (i.e. CHO and NAA).
Another study, performed in pediatric population has
shown a significant increase in Cho in left but not right
DLPFC in MDD patients versus control subjects. Simi-
larly to our findings, no significant differences in NAA or
Cr were observed between case-control pairs21. One stu-
dy in amygdala22 and another in basal ganglia23 reported
increased NAA levels after antidepressant treatment in
MDD patients, the effect we did not find in our pi-
lot-study. The reason may be related to NAA changes in
specific brain region, or to MDD that was comorbid to
PTSD.
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Fig. 2. NAA/Cr ratios for each of 11 responders, before (grey) and
after (black) the 3–6 weeks antidepressant treatment.
Fig. 3. CHO/Cr ratios for each of 11 responders, before (grey) and
after (black) the 3–6 weeks antidepressant treatment.
Previous studies analyzing changes in CHO/Cr have
shown consistent decrease in CHO/Cr levels in MDD pa-
tients after antidepressant treatment, although different
regions than DLPFC were analyzed. A meta-analysis has
displayed that MDD patients had higher CHO/Cr values
than healthy controls in the basal ganglia, but not in the
frontal lobe16.
Our pilot-study could not provide definite answer
about the nature of increase in CHO/Cr ratio in patients
with PTSD comorbid with MDD. Namely, it could be ei-
ther specific to certain brain regions such as DLPFC, or
this change could be caused by (also possibly) different
etiology of depression in patients with MDD comorbid to
PTSD. Additional studies are needed to clarify possible
region-specific differences in brain metabolite changes
after antidepressant treatments both in MDD patient
population and in population of patients suffering from
MDD comorbid to other psychiatric disorders. Clearly,
besides a small number of studies available, the problem
is also in great inconsistence in those previously pub-
lished. Differences in comorbidity, age and, perhaps the
most important, drugs subjects currently use or have
used before, make any meta analysis of the result virtu-
ally impossible. Thus, besides increasing only number of
studies, a consensus on their methodology is very much
needed.
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PROMJENE RAZINA MO@DANIH METABOLITA MJERENIH MAGNETSKOM REZONANTNOM
SPEKTROSKOPIJOM U ISPITANIKA S KOMORBIDITETOM DEPRESIJE I POSTTRAUMATSKOG
STRESNOG POREME]AJA KOJI SU ODGOVORILI NA ANTIDEPRESIVNO LIJE^ENJE
S A @ E T A K
U ovom pilot-ispitivanju, provedenom na 11 ispitanika, koristili smo metodu protonske magnentno rezonantne spek-
troskopije (1H-MRS) kako bismo prikazali promjene u osoba koje su imale pozitivan rani odgovor (3–6 tjedana) na
antidepresivno lije~enje selektivnim inhibitorima ponovne pohrane serotonina (SSRI). Svi ispitanici imali su dijagnozu
te{ke rekurentne depresije u komorbiditetu s posttraumatskim stresnim poreme}ajem (PTSP). Magnetskom spektro-
skopijom na ure|aju od 3T promatrano je podru~je dorzolateralnog prefrontalnog korteksa. Iz ve}eg uzorka izabrani su
oni ispitanici koji su pokazali rani odgovor na antidepresivno lije~enje tijekom 3–6 tjedana, mjereno ljestvicom Beck De-
pression Inventory (BDI). Metodom 1H-MRS mjerene su razine neuronskog markera N-acetil-aspartata (NAA), kolina
(CHO) i kretina (Cr). Izme|u prvog i drugog spektroskopskog mjerenja nije bilo zna~ajnih razlika u omjeru NAA/Cr
(p=0,751). S druge strane, omjeri CHO/Cr pokazali su tendenciju pove}anja sa srednjom vrijednosti na prvommjerenju
od 1,09 (SD=0,22), dok je srednja vrijednost na drugom mjerenju iznosila 1,25 (SD=0,24), {to je rezultiralo statisti~ki
zna~ajnom razlikom (p=0,015). Zna~ajno pove}anje omjera kolina prema kreatinu od prvog do drugog spektroskopskog
mjerenja, tijekom antidepresivnog lije~enja, u usporedbi s gotovo identi~nim vrijednostima omjera NAA prema krea-
tinu, sugerira da bi za mehanizam ranog odgovora na lije~enje antidepresivnim lijekovima mogao biti odgovorno poja-
~ano prepravljanje stani~nih membrana.
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